PMID- 33126340
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - T cell immunoglobulin and mucin domain-3 is associated with disease activity and 
      progressive joint damage in rheumatoid arthritis patients.
PG  - e22892
LID - 10.1097/MD.0000000000022892 [doi]
LID - e22892
AB  - T cell immunoglobulin and mucin domain-3 (TIM-3) is a surface molecule expressed 
      on immune cells which play a role in immune regulation. The aims of the present 
      study were to determine whether circulating soluble T cell immunoglobulin domain 
      and mucin-3 (sTIM-3) are elevated in rheumatoid arthritis (RA) patients, and 
      investigate the relationships between sTIM-3 and clinical features of RA.The 
      study included 116 patients with established RA and 27 healthy control subjects. 
      Serum levels of sTIM-3 were measured via the enzyme-linked immunosorbent assays 
      (ELISA). Correlations between serum sTIM-3 and a range of parameters including 
      anti-citrullinated peptide antibody (ACPA) titer, erythrocyte sedimentation rate 
      (ESR), and matrix metalloproteinase-3 (MMP-3) were assessed.Serum sTIM-3 was 
      significantly elevated in RA patients compared with those in healthy subjects, 
      and it was positively correlated with ACPA titer (r = 0.27 P = .005), ESR 
      (r = 0.27, P = .004) and MMP-3 (r = 0.35, P < .001). In RA patients with high 
      ACPA titers (>/=200 U/mL), sTIM-3 was not correlated with ESR or MMP-3. Whereas, 
      sTIM-3 was significantly correlated with ESR and MMP-3 in RA patients with low 
      ACPA titers (<200 U/mL).Serum sTIM-3 was increased in RA patients, and it was 
      associated with proinflammatory markers and disease activity in RA patients under 
      a particular ACPA status. Our data suggest that circulating sTIM-3 may be a 
      useful biomarker for the determination of disease activity in RA patients.
FAU - Matsumoto, Haruki
AU  - Matsumoto H
AD  - Department of Rheumatology, Fukushima Medical University School of Medicine, 1 
      Hikarigaoka, Fukushima, Fukushima, Japan.
FAU - Fujita, Yuya
AU  - Fujita Y
FAU - Asano, Tomoyuki
AU  - Asano T
FAU - Matsuoka, Naoki
AU  - Matsuoka N
FAU - Temmoku, Jumpei
AU  - Temmoku J
FAU - Sato, Shuzo
AU  - Sato S
FAU - Yashiro-Furuya, Makiko
AU  - Yashiro-Furuya M
FAU - Watanabe, Hiroshi
AU  - Watanabe H
FAU - Migita, Kiyoshi
AU  - Migita K
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Citrullinated Protein Antibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Hepatitis A Virus Cellular Receptor 2)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Anti-Citrullinated Protein Antibodies/*blood
MH  - *Arthritis, Rheumatoid/blood/diagnosis/physiopathology
MH  - Biomarkers/blood
MH  - Blood Sedimentation
MH  - Correlation of Data
MH  - Disease Progression
MH  - Female
MH  - Hepatitis A Virus Cellular Receptor 2/*blood
MH  - Humans
MH  - Joints/immunology/pathology
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Monitoring, Immunologic/methods
MH  - Patient Acuity
PMC - PMC7598883
COIS- KM has received research grants from Chugai, Pfizer, and AbbVie. Rest of the 
      authors have no conflicts of interests to disclose.
EDAT- 2020/11/01 06:00
MHDA- 2020/11/13 06:00
PMCR- 2020/10/30
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
PHST- 2020/10/30 00:00 [pmc-release]
AID - 00005792-202010300-00044 [pii]
AID - MD-D-20-04574 [pii]
AID - 10.1097/MD.0000000000022892 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22892. doi: 
      10.1097/MD.0000000000022892.